Liver disease in adult transfusion-dependent beta-thalassaemic patients: Investigating the role of iron overload and chronic HCV infection

Liver International

Volumn 33, Issue 3, 2013, Pages 420-427

  Kountouras, Dimitrios ^a   Tsagarakis, Nikolaos J ^a   Fatourou, Evangelia ^a   Dalagiorgos, Efthimios ^a   Chrysanthos, Nikolaos ^a   Berdoussi, Helen ^a   Vgontza, Niki ^b   Karagiorga, Markissia ^c   Lagiandreou, Athanasios ^b   Kaligeros, Konstantinos ^d   Voskaridou, Ersi ^e   Roussou, Paraskevi ^a   Diamanti Kandarakis, Evanthia ^a   Koskinas, John ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HIPPOKRATION HOSPITAL   (Greece)

^c AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^d 1st IKA Hospital   (Greece)

^e LAIKO GENERAL HOSPITAL   (Greece)

Author keywords

HCV; Iron; Liver fibrosis; Thalassaemia

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; FERRITIN;

ADOLESCENT; ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BETA THALASSEMIA; BETA THALASSEMIA MAJOR; BLOOD TRANSFUSION; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE SEVERITY; FEMALE; FERRITIN BLOOD LEVEL; GENDER; GENOTYPE; GREECE; HEMATOLOGIC DISEASE; HEPATITIS C; HUMAN; HUMAN TISSUE; INFLAMMATION; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LIVER DISEASE; LIVER FIBROSIS; LIVER HEMOSIDEROSIS; MALE; SCHOOL CHILD;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BETA-THALASSEMIA; BIOPSY; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FERRITINS; GREECE; HEPATITIS C; HUMANS; IRON OVERLOAD; LIVER DISEASES; MIDDLE AGED; TRANSAMINASES;

EID: 84873741362     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12095     Document Type: Article

References (32)

1. Berdoukas V, Farmaki K, Wood JC, Coates T. Iron chelation in thalassemia: time to reconsider our comfort zones. Expert Rev Hematol 2011; 4: 17-26.
2. Telfer P. Update on survival in thalassemia major. Hemoglobin 2009; 33(Suppl 1): S76-80.
3. Borgna-Pignatti C, Gamberini MR. Complications of thalassemia major and their treatment. Expert Rev Hematol 2011; 4: 353-66.
4. Cohen AR, Galanello R, Pennell DJ, Cunningham MJ, Vichinsky E. Thalassemia. Hematology Am Soc Hematol Educ Program 2004; 2004: 14-34.
5. Del Vecchio GC, Nigro A, Giordano P, De MD. Management of liver disease in thalassemia: main drug targets for a correct therapy. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 373-8.
6. Di M. V, Capra M, Gagliardotto F, et al. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008; 93: 1243-6.
7. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
8. Ardalan FA, Osquei MR, Toosi MN, Irvanloo G. Synergic effect of chronic hepatitis C infection and beta thalassemia major with marked hepatic iron overload on liver fibrosis: a retrospective cross-sectional study. BMC Gastroenterol 2004; 4: 17.
9. Aldouri MA, Wonke B, Hoffbrand AV, et al. Iron state and hepatic disease in patients with thalassaemia major, treated with long term subcutaneous desferrioxamine. J Clin Pathol 1987; 40: 1353-9.
10. Chen AC, Peng CT, Wu SF, et al. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia. Hemoglobin 2006; 30: 209-14.
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
12. Angelucci E, Muretto P, Nicolucci A, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21.
13. Liang TJ, Rehermann B, Seeff LB, Hoofnagle JH. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med 2000; 132: 296-305.
14. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
15. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349: 825-32.
16. Wright M, Goldin R, Fabre A, et al. Measurement and determinants of the natural history of liver fibrosis in hepatitis C virus infection: a cross sectional and longitudinal study. Gut 2003; 52: 574-9.
17. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.
18. Minola E, Prati D, Suter F, et al. Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C. Blood 2002; 99: 4588-91.
19. Ramm GA, Ruddell RG. Iron homeostasis, hepatocellular injury, and fibrogenesis in hemochromatosis: the role of inflammation in a noninflammatory liver disease. Semin Liver Dis 2010; 30: 271-87.
20. Diwakaran HH, Befeler AS, Britton RS, Brunt EM, Bacon BR. Accelerated hepatic fibrosis in patients with combined hereditary hemochromatosis and chronic hepatitis C infection. J Hepatol 2002; 36: 687-91.
21. Lin TJ, Liao LY, Lin SY, Lin CL, Chang TA. Influence of iron on the severity of hepatic fibrosis in patients with chronic hepatitis C. World J Gastroenterol 2006; 12: 4897-901.
22. Prati D, Maggioni M, Milani S, et al. Clinical and histological characterization of liver disease in patients with transfusion-dependent beta-thalassemia. A multicenter study of 117 cases. Haematologica 2004; 89: 1179-86.
23. Wu SF, Peng CT, Wu KH, Tsai CH. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients. Hemoglobin 2006; 30: 215-8.
24. Papastamataki M, Delaporta P, Premetis E, et al. Evaluation of liver fibrosis in patients with thalassemia: the important role of hyaluronic acid. Blood Cells Mol Dis 2010; 45: 215-8.
25. Muretto P, Angelucci E, Lucarelli G. Reversibility of cirrhosis in patients cured of thalassemia by bone marrow transplantation. Ann Intern Med 2002; 136: 667-72.
26. Tondury P, Zimmermann A, Nielsen P, Hirt A. Liver iron and fibrosis during long-term treatment with deferiprone in Swiss thalassaemic patients. Br J Haematol 1998; 101: 413-5.
27. Li CK, Chik KW, Lam CW, et al. Liver disease in transfusion dependent thalassaemia major. Arch Dis Child 2002; 86: 344-7.
28. Berdoukas V, Bohane T, Tobias V, et al. Liver iron concentration and fibrosis in a cohort of transfusion-dependent patients on long-term desferrioxamine therapy. Hematol J 2005; 5: 572-8.
29. Bonetti MG, Castriota-Scanderbeg A, Criconia GM, et al. Hepatic iron overload in thalassemic patients: proposal and validation of an MRI method of assessment. Pediatr Radiol 1996; 26: 650-6.
30. Anwar M, Nadeem A, Jamal S, et al. Effect of HCV infection on hepatic fibrosis in patients of thalassaemia major. J Coll Physicians Surg Pak 2006; 16: 200-3.
31. de VS, Sanna G, Cornacchia G, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. Arch Dis Child 1980;55:43-5.
32. Siagris D, Giannakoulas N, Christofidou M, et al. Virological, immunological and histological aspects in adult beta-thalassemic patients with chronic hepatitis C virus infection. Liver Int 2004; 24: 204-9.